The economic value of increasing geospatial access to tetanus toxoid immunization in Mozambique

Vaccine

Volumn 34, Issue 35, 2016, Pages 4161-4165

  Haidari, Leila A ^a   Brown, Shawn T ^a   Constenla, Dagna ^b   Zenkov, Eli ^a   Ferguson, Marie ^b   de Broucker, Gatien ^b   Ozawa, Sachiko ^b   Clark, Samantha ^b   Lee, Bruce Y ^b  

^a CARNEGIE MELLON UNIVERSITY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Access; Geospatial analysis; Immunization; Tetanus

Indexed keywords

TETANUS TOXOID;

ARTICLE; DRUG COST; DRUG EFFICACY; HEALTH CARE ACCESS; HEALTH CENTER; HUMAN; MEDICAL SUBJECT HEADINGS; MOZAMBIQUE; NEWBORN; NEWBORN TETANUS; PREGNANT WOMAN; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TRAVEL; VACCINATION; COST OF ILLNESS; ECONOMICS; FEMALE; GEOGRAPHY; HEALTH CARE DELIVERY; INFANT; PREGNANCY; PREVENTIVE HEALTH SERVICE; SPATIAL ANALYSIS; SUPPLY AND DISTRIBUTION; TETANUS;

COST OF ILLNESS; FEMALE; GEOGRAPHY; HEALTH SERVICES ACCESSIBILITY; HUMANS; IMMUNIZATION PROGRAMS; INFANT; MOZAMBIQUE; PREGNANCY; PREGNANT WOMEN; SPATIAL ANALYSIS; TETANUS; TETANUS TOXOID; TRAVEL;

EID: 84977643929     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.06.065     Document Type: Article

References (29)

1. [1] Centers for Disease Control and Prevention, Epidemiology and prevention of vaccine-preventable diseases. 13th ed., 2015, Public Health Foundation, Washington, D.C.
2. [2] World Health Organization (WHO), Tetanus vaccine: WHO position paper. Wkly Epidemiol Rec 81 (2006), 197–208.
3. [3] World Health Organization (WHO). Neonatal tetanus. < http://www.who.int/immunization/monitoring_surveillance/burden/vpd/surveillance_type/active/neonatal_tetanus/en/>.
4. [4] World Health Organization (WHO). Global and regional immunization profile; 2015. < http://www.who.int/immunization/monitoring_surveillance/data/gs_gloprofile.pdf?ua=1>.
5. [5] Lee, B.Y., Mehrotra, A., Burns, R.M., Harris, K.M., Alternative vaccination locations: who uses them and can they increase flu vaccination rates?. Vaccine 27 (2009), 4252–4256.
6. [6] Hipgrave, D.B., Alderman, K.B., Anderson, I., Soto, E.J., Health sector priority setting at meso-level in lower and middle income countries: lessons learned, available options and suggested steps. Soc Sci Med 102 (2014), 190–200.
7. [7] Instituto Nacional de Estatística Moçambique. < http://www.ine.gov.mz/>.
8. [8] Django. Version 1.8.7. < https://www.djangoproject.com/>.
9. [9] Leaflet. Version 0.7.7. < http://leafletjs.com/>.
10. [10] OpenStreetMap. < https://www.openstreetmap.org/>.
11. [11] World Health Organization (WHO). PQS catalogue: prequalified devices and equipment. < http://apps.who.int/immunization_standards/vaccine_quality/pqs_catalogue/categorylist.aspx>.
12. [12] United States National Library of Medicine (NLM), National Institutes of Health (NIH). PubMed. < http://www.ncbi.nlm.nih.gov/pubmed/>.
13. [13] Elsevier. Scopus. < http://www.scopus.com/>.
14. [14] American Economic Association (AEA). EconLit. < https://www.aeaweb.org/econlit/>.
15. [15] Quddus, A., Luby, S., Rahbar, M., Pervaiz, Y., Neonatal tetanus: mortality rate and risk factors in Loralai District, Pakistan. Int J Epidemiol 31 (2002), 648–653.
16. [16] Miranda-Filho, D.B., Ximenes, R.A., Siqueira-Filha, N.T., Santos, A.C., Incremental costs of treating tetanus with intrathecal antitetanus immunoglobulin. Trop Med Int Health 18 (2013), 555–563.
17. [17] World Bank. GNI per capita, Atlas method; 2015. < http://data.worldbank.org/indicator/NY.GNP.PCAP.CD>.
18. [18] Griffiths, U.K., Wolfson, L.J., Quddus, A., Younus, M., Hafiz, R.A., Incremental cost-effectiveness of supplementary immunization activities to prevent neonatal tetanus in Pakistan. Bull World Health Organ 82 (2004), 643–651.
19. [19] World Health Organization, The global burden of disease: 2004 update. 2008, World Health Organization, Geneva, Switzerland.
20. [20] Murray, C.J.L., Lopez, L., (eds.) The global burden of disease, vol. 1, 1996, Harvard University Press, Cambridge, MA.
21. [21] Perry, H., Weierbach, R., Hossain, I., Islam, R., Tetanus toxoid immunization coverage among women in zone 3 of Dhaka city: the challenge of reaching all women of reproductive age in urban Bangladesh. Bull World Health Organ 76 (1998), 449–457.
22. [22] Abbas, A.A., Walker, G.J., Determinants of the utilization of maternal and child health services in Jordan. Int J Epidemiol 15 (1986), 404–407.
23. [23] Anokye, M., Mensah, J., Frimpong, F., Aboagye, E., Acheampong, N., Immunization coverage of pregnant women with tetanus toxoid vaccine in Dormaa East District-Brong Adaro Region, Ghana. Math Theory Model 4 (2014), 47–56.
24. [24] Naeem, M., Khan, M.Z., Abbas, S.H., Adil, M., Khan, A., Naz, S.M., et al. Coverage and factors associated with tetanus toxoid vaccination among married women of reproductive age: a cross sectional study in Peshawar. J Ayub Med Coll Abbottabad 22 (2010), 136–140.
25. [25] Instituto Nacional de Estatistica, Ministerio da Saude, ORC Macro. Mocambique Inquerito Demografico e de Saude. Calverton, MD: Demographic and Health Surveys (DHS); 2005.
26. [26] Mozambique Ministry of Health. Comprehensive Multi-Year Plan (cMYP) 2012–2016; 2011. < http://www.gavi.org/Country/Mozambique/Documents/CMYPs/Comprehensive-multi-year-plan-for-2012-2016/>.
27. [27] World Health Organization Regional Office for Africa. Country-Programmes: Expanded program of immunization: Mozambique. Geneva: WHO; 2015. < http://www.afro.who.int/en/mozambique/country-programmes/mother-and-child-health/expanded-program-of-immunization.html>.
28. [28] Falagas, M.E., Zarkadoulia, E., Factors associated with suboptimal compliance to vaccinations in children in developed countries: a systematic review. Curr Med Res Opin 24 (2008), 1719–1741.
29. [29] Rainey, J.J., Watkins, M., Ryman, T.K., Sandhu, P., Bo, A., Banerjee, K., Reasons related to non-vaccination and under-vaccination of children in low and middle income countries: findings from a systematic review of the published literature, 1999–2009. Vaccine 29 (2011), 8215–8221.